|
Contents: |
TABLE OF CONTENTS
EXECUTIVE SUMMARY
INTRODUCTION
Disease overview
Acute Myeloid Leukemia
Epidemiology
Risk factors
DIAGNOSIS AND TREATMENT OF AML
Diagnosis and Staging
Treatment of AML
Overview
Stage specific breakdown of treatment
Remission therapy for AML
Country Analysis of current treatment practice
MARKET CONTEXT
Currently approved drugs
Cytarabine
Daunorubicin
Idamycin (idarubicin)
Mylotarg (gemtuzumab ozogamicin)
Cost of AML treatment
UNMET NEEDS IN AML
AML PIPELINE
Gleevac (STI 571)
Proleukin (Aldesleukin)
Ceplene (Histamine dihydrochloride)
SMART HuM195
Troxatyl (troxacitabine)
Annamycin
DX-8951f
Irofulven
Others
THE FUTURE DECODED
Future incidence of AML
Trends in the cancer market to 2007
The niche cancer market
Market forecast for AML pipeline
References
|
|